Shares of Alexion Pharmaceuticals, Inc. (ALXN) have traded between $94.59 – 141.86. The next earnings date is set for Jan 30, 2020. Let’s see how its prospects are shaping up.

What does Alexion Pharmaceuticals, Inc.(ALXN) do?

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

ALXN Insider Trading Insight

On 2019-07-01, Franchini Indrani Lall EVP, Chief Compliance Officer sold 4,500 shares of ALXN. That represents a value of $29,627. Not to be outdone, on 2019-06-21, Sarin Aradhana S – Sale sold578 shares of ALXN. These insiders are clearly in the know because they work closely with the company.

The PWR Consensus Price Target

The mean recommendation of Quanta Services, Inc. from top Wall Street analysts is a Strong Buy. That is based on 6 analysts who work on the Street. Based on 6 analysts offering 12 month price targets for Quanta Services in the last 3 months. The average price target is $49.17 with a high forecast of $51.00 and a low forecast of $46.00. The average price target represents a 19.17% increase from the last price of $41.26. Last week, several articles were published in financial papers about PWR and 39% Bearish while 61% Bullish.

PWR Intraday Trading

PWR is due to report earnings on Feb 20, 2020. In the last year the price has ranged from 32.12 – 44.1. Recently, Upperman Dorothy sold 5,764 shares of PWR. He is a $120,161 shareholder in PWR.

Looking for stocks similar to ALXN and PWR?

Here are some stocks to consider: